Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Plasma neopterin level as a marker of peripheral immune activation in amnestic mild cognitive impairment and Alzheimer's disease.

Parker DC, Mielke MM, Yu Q, Rosenberg PB, Jain A, Lyketsos CG, Fedarko NS, Oh ES.

Int J Geriatr Psychiatry. 2013 Feb;28(2):149-54. doi: 10.1002/gps.3802. Epub 2012 Apr 27.

2.

[Systemic inflammatory markers in age-associated cognitive impairment and Alzheimer's disease].

Kliushnik TP, Androsova LV, Mikhaylova NM, Kolykhalov IV, Zozulya SA, Dupin AM.

Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(7):74-79. doi: 10.17116/jnevro20171177174-79. Russian.

PMID:
28805765
3.

Emerging new biomarkers of Alzheimer's disease.

Kapoor S.

Int J Geriatr Psychiatry. 2013 Aug;28(8):880. doi: 10.1002/gps.3923. No abstract available.

PMID:
23832547
4.

Serum levels of inflammation factors and cognitive performance in amnestic mild cognitive impairment: a Chinese clinical study.

Zhao SJ, Guo CN, Wang MQ, Chen WJ, Zhao YB.

Cytokine. 2012 Feb;57(2):221-5. doi: 10.1016/j.cyto.2011.11.006. Epub 2011 Dec 9.

PMID:
22154514
5.

High avidity HSV-1 antibodies correlate with absence of amnestic Mild Cognitive Impairment conversion to Alzheimer's disease.

Agostini S, Mancuso R, Baglio F, Cabinio M, Hernis A, Costa AS, Calabrese E, Nemni R, Clerici M.

Brain Behav Immun. 2016 Nov;58:254-260. doi: 10.1016/j.bbi.2016.07.153. Epub 2016 Jul 25.

PMID:
27470229
6.

Plasma SUMO1 Protein is Elevated in Alzheimer's Disease.

Cho SJ, Yun SM, Lee DH, Jo C, Ho Park M, Han C, Ho Koh Y.

J Alzheimers Dis. 2015;47(3):639-43. doi: 10.3233/JAD-150103.

PMID:
26401699
7.

The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease.

Wang T, Xiao S, Liu Y, Lin Z, Su N, Li X, Li G, Zhang M, Fang Y.

Int J Geriatr Psychiatry. 2014 Jul;29(7):713-9. doi: 10.1002/gps.4053. Epub 2013 Dec 7.

PMID:
24318929
8.

Increased apoptosis in the platelets of patients with Alzheimer's disease and amnestic mild cognitive impairment.

Zhao S, Zhao J, Zhang T, Guo C.

Clin Neurol Neurosurg. 2016 Apr;143:46-50. doi: 10.1016/j.clineuro.2016.02.015. Epub 2016 Feb 11.

PMID:
26895209
9.

Plasma amyloid-β oligomers and soluble tumor necrosis factor receptors as potential biomarkers of AD.

Zhang J, Peng M, Jia J.

Curr Alzheimer Res. 2014 May;11(4):325-31.

PMID:
24635842
10.

Amnestic mild cognitive impairment and conversion to Alzheimer's disease: insulin resistance and glycoxidation as early biomarker clusters.

Monacelli F, Borghi R, Cammarata S, Nencioni A, Piccini A, Tabaton M, Odetti P.

J Alzheimers Dis. 2015;45(1):89-95. doi: 10.3233/JAD-142511.

PMID:
25471189
11.

Decreased serum levels of the angiogenic factors VEGF and TGF-β1 in Alzheimer's disease and amnestic mild cognitive impairment.

Huang L, Jia J, Liu R.

Neurosci Lett. 2013 Aug 29;550:60-3. doi: 10.1016/j.neulet.2013.06.031. Epub 2013 Jul 1.

PMID:
23827227
12.

A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease.

Olazarán J, Gil-de-Gómez L, Rodríguez-Martín A, Valentí-Soler M, Frades-Payo B, Marín-Muñoz J, Antúnez C, Frank-García A, Acedo-Jiménez C, Morlán-Gracia L, Petidier-Torregrossa R, Guisasola MC, Bermejo-Pareja F, Sánchez-Ferro Á, Pérez-Martínez DA, Manzano-Palomo S, Farquhar R, Rábano A, Calero M.

J Alzheimers Dis. 2015;45(4):1157-73. doi: 10.3233/JAD-142925.

PMID:
25649659
13.

Plasma fatty acid lipidomics in amnestic mild cognitive impairment and Alzheimer's disease.

Iuliano L, Pacelli A, Ciacciarelli M, Zerbinati C, Fagioli S, Piras F, Orfei MD, Bossù P, Pazzelli F, Serviddio G, Caltagirone C, Spalletta G.

J Alzheimers Dis. 2013;36(3):545-53. doi: 10.3233/JAD-122224.

PMID:
23635405
14.

Increase in the IgG avidity index due to herpes simplex virus type 1 reactivation and its relationship with cognitive function in amnestic mild cognitive impairment and Alzheimer's disease.

Kobayashi N, Nagata T, Shinagawa S, Oka N, Shimada K, Shimizu A, Tatebayashi Y, Yamada H, Nakayama K, Kondo K.

Biochem Biophys Res Commun. 2013 Jan 18;430(3):907-11. doi: 10.1016/j.bbrc.2012.12.054. Epub 2012 Dec 19. Erratum in: Biochem Biophys Res Commun. 2014 Jul 18;450(1):925.

PMID:
23261465
15.

Increased Serum miR-206 Level Predicts Conversion from Amnestic Mild Cognitive Impairment to Alzheimer's Disease: A 5-Year Follow-up Study.

Xie B, Liu Z, Jiang L, Liu W, Song M, Zhang Q, Zhang R, Cui D, Wang X, Xu S.

J Alzheimers Dis. 2017;55(2):509-520.

PMID:
27662297
16.

The feasibility of utilizing plasma MiRNA107 and BACE1 messenger RNA gene expression for clinical diagnosis of amnestic mild cognitive impairment.

Wang T, Chen K, Li H, Dong S, Su N, Liu Y, Cheng Y, Dai J, Yang C, Xiao S.

J Clin Psychiatry. 2015 Feb;76(2):135-41. doi: 10.4088/JCP.13m08812.

PMID:
25742200
17.

Cerebrospinal fluid inflammatory markers in amnestic mild cognitive impairment.

Rizzi L, Roriz-Cruz M.

Geriatr Gerontol Int. 2017 Feb;17(2):239-245. doi: 10.1111/ggi.12704. Epub 2016 Jan 28.

PMID:
26818250
18.

Amyloid-Independent Amnestic Mild Cognitive Impairment and Serum Apolipoprotein A1 Levels.

Choi HJ, Seo EH, Yi D, Sohn BK, Choe YM, Byun MS, Lee JM, Woo JI, Lee DY.

Am J Geriatr Psychiatry. 2016 Feb;24(2):144-53. doi: 10.1016/j.jagp.2015.06.004. Epub 2015 Jun 26.

PMID:
26238231
19.

Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?

Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, Casadei V, Grimaldi LM.

J Neuroimmunol. 2000 Feb 1;103(1):97-102.

PMID:
10674995
20.

No relationship between lipoprotein-associated phospholipase A2, proinflammatory cytokines, and neopterin in Alzheimer's disease.

Savas S, Kabaroglu C, Alpman A, Sarac F, Yalcin MA, Parıldar Z, Ozkinay F, Kumral E, Akcicek F.

Exp Gerontol. 2016 May;77:1-6. doi: 10.1016/j.exger.2016.01.014. Epub 2016 Jan 29.

PMID:
26828804

Supplemental Content

Support Center